Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines

James L. Mohler; Andrew J. Armstrong; Robert R. Bahnson; Barry Boston; J. Erik Busby; Anthony Victor D'Amico; James A. Eastham; Charles A. Enke; Thomas Farrington; Celestia S. Higano; Eric Mark Horwitz; Philip W. Kantoff; Mark H. Kawachi; Michael Kuettel; Richard J. Lee; Gary R. MacVicar; Arnold W. Malcolm; David Miller; Elizabeth R. Plimack; Julio M. Pow-Sang; Mack Roach; Eric Rohren; Stan Rosenfeld; Sandy Srinivas; Seth A. Strope; Jonathan Tward; Przemyslaw Twardowski; Patrick C. Walsh; Maria Ho; Dorothy A. Shead

doi:10.6004/jnccn.2012.0114

Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D'Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-SangMack Roach, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, Dorothy A. Shead

Johns Hopkins Hospital

Research output: Contribution to journal › Review article › peer-review

185 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

Original language	English (US)
Pages (from-to)	1081-1087
Number of pages	7
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	10
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2012.0114
State	Published - Sep 1 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2012.0114

Cite this

Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T., Higano, C. S., Horwitz, E. M., Kantoff, P. W., Kawachi, M. H., Kuettel, M., Lee, R. J., MacVicar, G. R., Malcolm, A. W., Miller, D., Plimack, E. R., ... Shead, D. A. (2012). Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(9), 1081-1087. https://doi.org/10.6004/jnccn.2012.0114

Mohler, JL, Armstrong, AJ, Bahnson, RR, Boston, B, Busby, JE, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, T, Higano, CS, Horwitz, EM, Kantoff, PW, Kawachi, MH, Kuettel, M, Lee, RJ, MacVicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Roach, M, Rohren, E, Rosenfeld, S, Srinivas, S, Strope, SA, Tward, J, Twardowski, P, Walsh, PC, Ho, M & Shead, DA 2012, 'Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 9, pp. 1081-1087. https://doi.org/10.6004/jnccn.2012.0114

@article{9ac999369c0e468aa00f96bf5b902588,

title = "Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.",

author = "Mohler, {James L.} and Armstrong, {Andrew J.} and Bahnson, {Robert R.} and Barry Boston and Busby, {J. Erik} and D'Amico, {Anthony Victor} and Eastham, {James A.} and Enke, {Charles A.} and Thomas Farrington and Higano, {Celestia S.} and Horwitz, {Eric Mark} and Kantoff, {Philip W.} and Kawachi, {Mark H.} and Michael Kuettel and Lee, {Richard J.} and MacVicar, {Gary R.} and Malcolm, {Arnold W.} and David Miller and Plimack, {Elizabeth R.} and Pow-Sang, {Julio M.} and Mack Roach and Eric Rohren and Stan Rosenfeld and Sandy Srinivas and Strope, {Seth A.} and Jonathan Tward and Przemyslaw Twardowski and Walsh, {Patrick C.} and Maria Ho and Shead, {Dorothy A.}",

year = "2012",

month = sep,

day = "1",

doi = "10.6004/jnccn.2012.0114",

language = "English (US)",

volume = "10",

pages = "1081--1087",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - Prostate cancer, version 3.2012

T2 - Featured updates to the NCCN Guidelines

AU - Mohler, James L.

AU - Armstrong, Andrew J.

AU - Bahnson, Robert R.

AU - Boston, Barry

AU - Busby, J. Erik

AU - D'Amico, Anthony Victor

AU - Eastham, James A.

AU - Enke, Charles A.

AU - Farrington, Thomas

AU - Higano, Celestia S.

AU - Horwitz, Eric Mark

AU - Kantoff, Philip W.

AU - Kawachi, Mark H.

AU - Kuettel, Michael

AU - Lee, Richard J.

AU - MacVicar, Gary R.

AU - Malcolm, Arnold W.

AU - Miller, David

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Roach, Mack

AU - Rohren, Eric

AU - Rosenfeld, Stan

AU - Srinivas, Sandy

AU - Strope, Seth A.

AU - Tward, Jonathan

AU - Twardowski, Przemyslaw

AU - Walsh, Patrick C.

AU - Ho, Maria

AU - Shead, Dorothy A.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=84866562665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866562665&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0114

DO - 10.6004/jnccn.2012.0114

M3 - Review article

C2 - 22956807

AN - SCOPUS:84866562665

SN - 1540-1405

VL - 10

SP - 1081

EP - 1087

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this